VivoSim Labs Seeks Stockholder Approval for Reverse Split, Equity Plan Increase, and Warrant-Related Dilution

summarizeSummary

VivoSim Labs filed a preliminary proxy for its 2026 annual meeting, seeking stockholder approval for a reverse stock split, an increase in its equity plan share reserve, and the issuance of 4.7 million shares upon warrant exercise and repricing of older warrants—a move that would substantially dilute existing shareholders.

check_boxKey Events · Corporate Governance and Compliance · VIVS

• Reverse Stock Split Proposed

  Proposal 4 seeks authorization for a reverse stock split at a ratio between 1-for-[ ] and 1-for-[ ] (specific ratios to be determined), to be effected at the Board's discretion by September 30, 2027, without reducing authorized shares. The move aims to increase the stock price and maintain Nasdaq listing compliance.

• Equity Plan Share Increase

  Proposal 5 asks stockholders to approve an amendment to the 2022 Equity Incentive Plan to increase the share reserve by [ ] shares (specific number to be filled), with only 3,422 shares currently available for future grants.

• Warrant Issuance and Repricing Vote

  Proposal 6 seeks approval for the issuance of 4,705,883 shares upon exercise of common warrants from the July 2026 PIPE, and the reduction of the exercise price of May 2024 investor warrants from $9.60 to $0.85 per share. This is required by Nasdaq Listing Rule 5635(d) and the PIPE terms; if approved, it would cause significant dilution to existing stockholders.

• Annual Meeting Scheduled

  The annual meeting will be held virtually on September 30, 2026, with a record date of August 13, 2026. Stockholders will also vote on the election of two directors, ratification of the auditor, and an advisory vote on executive compensation.

auto_awesomeAnalysis · VIVS · Life Sciences

VivoSim Labs' preliminary proxy statement reveals a critical annual meeting agenda. The company is asking shareholders to approve a reverse stock split to boost its share price and maintain Nasdaq listing, following a recent delisting notice and subsequent compliance. It also seeks to increase shares under its equity incentive plan and, crucially, to approve the issuance of 4.7 million shares upon exercise of warrants from its July 2026 private placement and the repricing of older warrants from $9.60 to $0.85. This last proposal is required by Nasdaq rules and the PIPE terms; if approved, it would significantly dilute existing holders. The meeting is set for September 30, 2026, with a record date of August 13, 2026.